Intervention Review

Interferon in relapsing-remitting multiple sclerosis

  1. George PA Rice2,
  2. Barbara Incorvaia3,
  3. Luca M. Munari4,
  4. George Ebers5,
  5. Chris Polman6,
  6. Roberto D'Amico7,
  7. Elena Parmelli7,
  8. Graziella Filippini1,*

Editorial Group: Cochrane Multiple Sclerosis Group

Published Online: 23 OCT 2001

Assessed as up-to-date: 29 APR 2007

DOI: 10.1002/14651858.CD002002


How to Cite

Rice GPA, Incorvaia B, Munari LM, Ebers G, Polman C, D'Amico R, Parmelli E, Filippini G. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD002002. DOI: 10.1002/14651858.CD002002.

Author Information

  1. 1

    Fondazione I.R.C.C.S. - Istituto Neurologico C.Besta, Neuroepidemiology Unit, Milano, Italy

  2. 2

    University of Western Ontario, Clinical Neurological Sciences, London, Ontario, Canada

  3. 3

    Osservatorio Epidemiologico - Regione Umbria, Cochrane Neurological Network, Perugia, Italy

  4. 4

    Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy

  5. 5

    University of Oxford, Clinical Neurology, Oxford, UK

  6. 6

    VU Medical Centre, Neurology, Amsterdam, Netherlands

  7. 7

    University of Modena and Reggio Emilia, Department of Oncology and Hematology, Modena, Italy

*Graziella Filippini, Neuroepidemiology Unit, Fondazione I.R.C.C.S. - Istituto Neurologico C.Besta, via Celoria 11, Milano, 20133, Italy. gfilippini@istituto-besta.it.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 23 OCT 2001

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    N. Melzer, S. G. Meuth, Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies, Clinical & Experimental Immunology, 2014, 175, 3
  2. 2
    Carolyn E. Schwartz, Brian R. Quaranto, Bruce D. Rapkin, Brian C. Healy, Timothy Vollmer, Mirjam A. G. Sprangers, Fluctuations in appraisal over time in the context of stable versus non-stable health, Quality of Life Research, 2014, 23, 1, 9

    CrossRef

  3. 3
    Alan M. Palmer, New and emerging immune-targeted drugs for the treatment of multiple sclerosis, British Journal of Clinical Pharmacology, 2014, 78, 1
  4. 4
    Paul W. O’Connor, Jiwon Oh, Multiple Sclerosis and Related Disorders, 2014,

    CrossRef

  5. 5
    John Zajicek, Neurological Rehabilitation, 2013,

    CrossRef

  6. 6
    Charity Evans, Jennifer Tam, Elaine Kingwell, Joel Oger, Helen Tremlett, Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study, Clinical Therapeutics, 2012, 34, 2, 341

    CrossRef

  7. 7
    Jürgen Kasper, France Légaré, Fülöp Scheibler, Friedemann Geiger, Turning signals into meaning –‘Shared decision making’ meets communication theory, Health Expectations, 2012, 15, 1
  8. 8
    J. Kasper, S. Köpke, I. Mühlhauser, M. Nübling, C. Heesen, Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial, European Journal of Neurology, 2008, 15, 12
  9. 9
    . Fernndez Fernndez, V.E. Fernndez, Tratamiento de la esclerosis m?ltiple. Tratamiento de los brotes. Tratamiento de fondo. Esteroides. Inmunosupresores. Interfer?n beta. Indicaciones. Posolog?a. Contraindicaciones. Efectos secundarios. Criterios de asociaci?n, Medicine - Programa de Formaci?n M?dica Continuada Acreditado, 2007, 9, 76, 4878

    CrossRef

  10. 10
    Meike Mitsdoerffer, Bettina Schreiner, Bernd C. Kieseier, Oliver Neuhaus, Johannes Dichgans, Hans-Peter Hartung, Michael Weller, Heinz Wiendl, Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis, Journal of Neuroimmunology, 2005, 159, 1-2, 155

    CrossRef

  11. 11
    Bettina Schreiner, Meike Mitsdoerffer, Bernd C. Kieseier, Lieping Chen, Hans-Peter Hartung, Michael Weller, Heinz Wiendl, Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis, Journal of Neuroimmunology, 2004, 155, 1-2, 172

    CrossRef

  12. 12
    Richard A.C Hughes, Interferon beta 1a for secondary progressive multiple sclerosis, Journal of the Neurological Sciences, 2003, 206, 2, 199

    CrossRef

  13. 13
    Jian Zhang, Yousheng Xiao, Lian Meng, Xiaobo Yang, Shengliang Shi, Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis, The Cochrane Library,
  14. 14
    Alfonso Ciccone, Sandro Beretta, Fabio Brusaferri, Ian Galea, Alessandra Protti, Chiara Spreafico, Corticosteroids for the long-term treatment in multiple sclerosis, The Cochrane Library,
  15. 15
    Alessandro Liberati, Lorenzo P. Moja, Ivan Moschetti, Evidence-based Medicine: Its Contributions in the Way We Search, Appraise and Apply Scientific Information to Patient Care,
  16. 16
    Graziella Filippini, Cinzia Del Giovane, Laura Vacchi, Roberto D'Amico, Carlo Di Pietrantonj, Deirdre Beecher, Georgia Salanti, Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis, The Cochrane Library,
  17. 17
    JI Rojas, M Romano, A Ciapponi, L Patrucco, E Cristiano, Interferon beta for primary progressive multiple sclerosis, The Cochrane Library,
  18. 18
    Loredana La Mantia, Laura Vacchi, Carlo Di Pietrantonj, George Ebers, Marco Rovaris, Sten Fredrikson, Graziella Filippini, Interferon beta for secondary progressive multiple sclerosis, The Cochrane Library,
  19. 19
    Loredana La Mantia, George Ebers, Sten Fredrikson, Graziella Filippini, Interferon beta for secondary progressive multiple sclerosis, The Cochrane Library,
  20. 20
    G PA Rice, GC Ebers, S Fredrikson, D Mason, F Tesser, G Filippini, Interferon beta for secondary progressive multiple sclerosis, The Cochrane Library,
  21. 21
    Loredana La Mantia, Alberto Vaona, Marco Rovaris, Francesco Berardo, Serena Frau, Anna Gandini, Anna Longobardi, Giulio Rigon, Carlo Di Pietrantonj, Bianca Weinstock-Guttman, Interferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosis, The Cochrane Library,
  22. 22
    Loredana La Mantia, Carlo Di Pietrantonj, Marco Rovaris, Giulio Rigon, Serena Frau, Francesco Berardo, Anna Gandini, Anna Longobardi, Bianca Weinstock-Guttman, Alberto Vaona, Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis, The Cochrane Library,
  23. 23
    Filippo Martinelli Boneschi, Laura Vacchi, Marco Rovaris, Ruggero Capra, Giancarlo Comi, Mitoxantrone for multiple sclerosis, The Cochrane Library,
  24. 24
    Filippo Martinelli Boneschi, Marco Rovaris, Ruggero Capra, Giancarlo Comi, Mitoxantrone for multiple sclerosis, The Cochrane Library,
  25. 25
    Richard AC Hughes, Jane Pritchard, Robert DM Hadden, Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome, The Cochrane Library,
  26. 26
    Richard AC Hughes, Jane Pritchard, Robert DM Hadden, Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome, The Cochrane Library,
  27. 27
    M Clerico, F Faggiano, J Palace, G Rice, M Tintorè, L Durelli, Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis, The Cochrane Library,
  28. 28
    Marinella Clerico, Fabrizio Faggiano, Jaqueline Palace, George PA Rice, Mar Tintorè Subirana, Luca Durelli, Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis, The Cochrane Library,